Overexpression of Estrogen Receptor α in Mammary Glands of Aging Mice Is Associated with a Proliferative Risk Signature and Generation of Estrogen Receptor α-Positive Mammary Adenocarcinomas.
Journal
The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
28
06
2022
revised:
29
08
2022
accepted:
28
09
2022
pmc-release:
01
01
2024
pubmed:
5
12
2022
medline:
20
12
2022
entrez:
4
12
2022
Statut:
ppublish
Résumé
Age is a risk factor for human estrogen receptor-positive breast cancer, with highest prevalence following menopause. While transcriptome risk profiling is available for human breast cancers, it is not yet developed for prognostication for primary or secondary breast cancer development utilizing at-risk breast tissue. Both estrogen receptor α (ER) and aromatase overexpression have been linked to human breast cancer. Herein, conditional genetically engineered mouse models of estrogen receptor 1 (Esr1) and cytochrome P450 family 19 subfamily A member 1 (CYP19A1) were used to show that induction of Esr1 overexpression just before or with reproductive senescence and maintained through age 30 months resulted in significantly higher prevalence of estrogen receptor-positive adenocarcinomas than CYP19A1 overexpression. All adenocarcinomas tested showed high percentages of ER
Identifiants
pubmed: 36464513
pii: S0002-9440(22)00317-0
doi: 10.1016/j.ajpath.2022.09.008
pmc: PMC9768686
pii:
doi:
Substances chimiques
Estrogen Receptor alpha
0
Cyp19a1 protein, mouse
EC 1.14.14.1
Esr1 protein, mouse
0
Aromatase
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-120Subventions
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NCI NIH HHS
ID : UH2 CA213388
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA213388
Pays : United States
Informations de copyright
Copyright © 2023 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Références
Biol Reprod. 2021 Oct 11;105(4):1030-1042
pubmed: 34086879
Am J Pathol. 2003 Nov;163(5):1713-9
pubmed: 14578170
Mol Med. 2020 Apr 9;26(1):33
pubmed: 32272902
NPJ Breast Cancer. 2020 Sep 7;6:41
pubmed: 32964115
Curr Protoc Mouse Biol. 2015 Jun 01;5(2):95-133
pubmed: 26069080
Mol Oncol. 2007 Jun;1(1):97-119
pubmed: 19383289
Front Cell Dev Biol. 2018 Mar 29;6:35
pubmed: 29651417
Endocr Relat Cancer. 2014 Feb 27;21(2):263-73
pubmed: 24322303
Sci Rep. 2020 Jul 6;10(1):11044
pubmed: 32632202
Breast Cancer Res Treat. 2002 Dec;76(3):221-36
pubmed: 12462383
J Steroid Biochem Mol Biol. 2015 Jan;145:172-8
pubmed: 24751707
Front Med (Lausanne). 2018 Sep 04;5:248
pubmed: 30234119
Anticancer Res. 2009 Oct;29(10):3897-901
pubmed: 19846925
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Cancer Res. 2005 Feb 1;65(3):681-5
pubmed: 15705859
PLoS One. 2012;7(8):e43624
pubmed: 22952723
Genome Biol. 2014;15(12):550
pubmed: 25516281
Br J Cancer. 2021 Mar;124(6):1150-1159
pubmed: 33414541
Br J Cancer. 2014 Jun 10;110(12):2905-13
pubmed: 24853182
Transgenic Res. 2002 Aug;11(4):361-72
pubmed: 12212839
Cells. 2021 Oct 31;10(11):
pubmed: 34831189
J Bone Oncol. 2020 Jul 20;24:100304
pubmed: 32760644
Lab Anim. 2020 Jun;54(3):225-238
pubmed: 31403890
Anat Physiol. 2012 Jun 25;Suppl 12:
pubmed: 24575359
J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):271-7
pubmed: 18663563
Oncogene. 2008 May 15;27(22):3186-93
pubmed: 18071314
Mol Endocrinol. 2011 Apr;25(4):549-63
pubmed: 21292825
Breast Cancer Res. 2014 Mar 17;16(2):R26
pubmed: 24636070
Crit Rev Oncol Hematol. 2008 Apr;66(1):65-74
pubmed: 17949989
Br J Surg. 2022 Apr 19;109(5):411-417
pubmed: 35194632
Metabolites. 2018 Feb 28;8(1):
pubmed: 29495652
Int J Mol Sci. 2020 Jan 30;21(3):
pubmed: 32019139
BMC Cancer. 2016 Nov 18;16(1):904
pubmed: 27863473
J Natl Cancer Inst. 2022 Mar 8;114(3):391-399
pubmed: 34747484
EBioMedicine. 2021 Jul;69:103451
pubmed: 34161883
Dis Model Mech. 2017 Apr 1;10(4):359-371
pubmed: 28381598
J Gerontol A Biol Sci Med Sci. 2021 Mar 31;76(4):552-560
pubmed: 33211821
Genes Cancer. 2010 Jun;1(6):629-40
pubmed: 21779462
Pathol Res Pract. 2022 Jan;229:153729
pubmed: 34952422
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Res. 2011 Aug 15;71(16):5477-87
pubmed: 21840986
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33658388
Carcinogenesis. 2015 Jan;36(1):122-32
pubmed: 25421723
Breast Cancer Res. 2009;11(3):R26
pubmed: 19426500
Oncotarget. 2015 Dec 22;6(41):43244-54
pubmed: 26657114
Semin Cell Dev Biol. 2021 Jun;114:93-112
pubmed: 33082117
Cancer Cell Int. 2020 Apr 15;20:123
pubmed: 32322170
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Oncol Ther. 2020 Dec;8(2):231-250
pubmed: 32700048
Sci Rep. 2022 Apr 22;12(1):6159
pubmed: 35459280
Cancer Prev Res (Phila). 2017 Apr;10(4):244-254
pubmed: 28283467
Adv Cancer Res. 2004;92:81-94
pubmed: 15530557
Oncogene. 2008 Jan 31;27(6):794-802
pubmed: 17653086
Cell Growth Differ. 1996 Jan;7(1):13-20
pubmed: 8788029
Mol Endocrinol. 2011 Aug;25(8):1326-36
pubmed: 21680658
Front Cell Dev Biol. 2022 Jan 26;10:804419
pubmed: 35155425
Lab Anim. 2017 Apr;51(2):160-169
pubmed: 27307423
Acta Pharmacol Sin. 2015 Jan;36(1):24-31
pubmed: 25500870
Biol Reprod. 2018 Jan 1;98(1):130-145
pubmed: 29165555
Breast Cancer Res. 2007;9(5):R59
pubmed: 17850661
Nat Biotechnol. 2014 Sep;32(9):896-902
pubmed: 25150836
Cell. 2000 Dec 8;103(6):843-52
pubmed: 11136970
Eur J Cancer. 2004 Dec;40(18):2717-25
pubmed: 15571953
Biomed Pharmacother. 2018 Aug;104:576-581
pubmed: 29803169
J Pathol. 2007 Jan;211(2):232-40
pubmed: 17200937
Endocr Relat Cancer. 2014 May 06;21(3):R195-208
pubmed: 24481326
Carcinogenesis. 2010 Jun;31(6):1124-31
pubmed: 20181624
Front Pharmacol. 2018 Dec 06;9:1345
pubmed: 30574087
Tumour Biol. 2015 Dec;36(12):9789-94
pubmed: 26159850
BMC Cancer. 2015 Jul 17;15:524
pubmed: 26183823